An unusual histologic variant of necrobiotic xanthogranuloma.

Am J Dermatopathol

Department of Dermatology, Venereology, and Allergology, University Hospital of Leipzig, Philipp-Rosenthal-Str. 23–25, Leipzig, Germany.

Published: April 2012

Necrobiotic xanthogranuloma (NXG) usually shows a stereotypical histopathologic presentation. However, few unusual cases have been published. We present a patient with NXG showing exceptional histopathologic features. NXG in our patient presents with exclusively dermal granulomatous inflammation mimicking interstitial granuloma annulare. Not only subcutaneous involvement, but also, evident zones of degenerated collagen, foam cells, and cholesterol clefts were missing. Moreover, the case shows overlaps with recently published granulomatous scleromyxedema. Some common clinical and histopathologic features of NXG and scleromyxedema might be based on shared underlying paraproteinemia.

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0b013e3182222aa8DOI Listing

Publication Analysis

Top Keywords

necrobiotic xanthogranuloma
8
histopathologic features
8
features nxg
8
unusual histologic
4
histologic variant
4
variant necrobiotic
4
xanthogranuloma necrobiotic
4
nxg
4
xanthogranuloma nxg
4
nxg stereotypical
4

Similar Publications

Foamy Cell Angiosarcoma Resembling a Xanthomatous Histiocytic Infiltrate Without Evidence of Vascular Malignancy.

J Cutan Pathol

December 2024

Department of Medicine, Division of Dermatology, St. Louis School of Medicine, Washington University, St. Louis, Missouri, USA.

Angiosarcoma is a rare and aggressive malignancy of endothelial cells with multiple subtypes. Foamy cell angiosarcoma is a rare variant in which endothelial cells demonstrate "foamy" cytoplasmic change. We present the case of a 59-year-old male who presented with progressive erythema and swelling of the midface and bilateral eyelids.

View Article and Find Full Text PDF
Article Synopsis
  • Intravenous immunoglobulin (IVIG) therapy shows promise for treating various dermatological autoimmune diseases due to its ability to modulate the immune system and low risk of severe side effects.
  • The exact mechanism of how IVIG works in autoimmune diseases is still debated, but it involves neutralizing harmful autoantibodies and preventing tissue damage.
  • While IVIG is primarily used off-label for conditions like dermatomyositis and systemic sclerosis, a key study (ProDERM 2022) demonstrated its effectiveness specifically for dermatomyositis, and it is commonly used as first-line treatment for scleromyxedema.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!